Drug Approval | May 08, 2024
USFDA accepts Bristol Myers Squibb’s application for subcutaneous nivolumab
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Subcutaneous nivolumab has potential to be the first and only subcutaneously administered PD-1 inhibitor
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Pelabresib recently met its primary endpoint of spleen volume reduction and demonstrated favorable trends in symptom improvement
This alliance brings together drug innovation capabilities of Glenmark and Ichnos to develop cutting-edge therapies for the treatment of hematological malignancies and solid tumors
Glenmark will be responsible for further developing, registering, and commercializing Envafolimab in India, Asia Pacific, Middle East and Africa, Russia, CIS, and Latin America
Comprehensive clinical development programs being initiated for each investigational candidate
The product will be manufactured at Lupin's Pithampur facility in India
C-CAR031 is based on a novel GPC3-targeting CAR-T (AZD5851) designed by AstraZeneca using their transforming growth factor-beta receptor II
Subscribe To Our Newsletter & Stay Updated
